For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 0 | 3 | -94* | 122 |
| Cost of revenue | 0 | - | -19* | 25 |
| Gross profit | 0 | - | -75* | 97 |
| General and administrative expenses | 470 | 245 | 113* | 283 |
| Research and development expenses | 4 | 7 | 8* | 42 |
| Total operating expenses | 474 | 252 | 121* | 325 |
| Loss from operations | -474 | -249 | -196* | -228 |
| Loss on patent assignment | 0 | - | -439* | - |
| Interest expense | 2 | 9 | 0* | 2 |
| Net income (loss) | -476 | -258 | -636 | -230 |
| Basic EPS | 0 | 0 | -0.002 | 0 |
| Diluted EPS | 0 | 0 | -0.002 | 0 |
| Basic Average Shares | 301,177,864 | 289,156,340 | 287,246,166 | 286,467,487 |
| Diluted Average Shares | 301,177,864 | 289,156,340 | 287,246,166 | 286,467,487 |
Cavitation Technologies, Inc. (CVAT)
Cavitation Technologies, Inc. (CVAT)